Bosh sahifaA1LN34 • BVMF
add
Alnylam Pharmaceuticals Inc Bdr
Yopilish kursi
71,74 R$
Yillik diapazon
36,23 R$ - 85,44 R$
Bozor kapitalizatsiyasi
31,33 mlrd USD
Oʻrtacha hajm
38,00
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 593,17 mln | 34,90% |
Joriy xarajat | 595,51 mln | 26,63% |
Sof foyda | -83,76 mln | 39,24% |
Sof foyda marjasi | -14,12 | 54,96% |
Har bir ulushga tushum | 0,06 | 107,79% |
EBITDA | -90,99 mln | 11,59% |
Amaldagi soliq stavkasi | 56,81% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 2,69 mlrd | 10,46% |
Jami aktivlari | 4,24 mlrd | 10,71% |
Jami passivlari | 4,17 mlrd | 3,02% |
Umumiy kapital | 67,09 mln | — |
Tarqatilgan aksiyalar | 129,46 mln | — |
Narxi/balansdagi bahosi | 137,96 | — |
Aktivlardan daromad | -6,23% | — |
Kapitaldan daromad | -9,44% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -83,76 mln | 39,24% |
Operatsiyalardan naqd pul | -94,66 mln | -217,71% |
Sarmoyadan naqd pul | -52,91 mln | 78,01% |
Moliyadan naqd pul | 31,00 mln | -20,98% |
Naqd pulning sof oʻzgarishi | -133,85 mln | 39,25% |
Boʻsh pul | -110,30 mln | -165,23% |
Haqida
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
Tashkil etilgan
14-iyn, 2002
Sayt
Xodimlar soni
2 230
